As of January 22, 2025, CytomX Therapeutics (CTMX) has a market cap of $65.550 million USD. According to our data, CytomX Therapeutics is ranked No.7994 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $65.55 M |
-18.68%
|
Dec 31, 2024 | $80.61 M |
-33.55%
|
Dec 29, 2023 | $0.12 B |
-3.13%
|
Dec 30, 2022 | $0.13 B |
-63.05%
|
Dec 31, 2021 | $0.34 B |
-33.89%
|
Dec 31, 2020 | $0.51 B |
-21.18%
|
Dec 31, 2019 | $0.65 B |
-44.97%
|
Dec 31, 2018 | $1.18 B |
-28.47%
|
Dec 29, 2017 | $1.65 B |
92.08%
|
Dec 30, 2016 | $0.86 B |
-47.34%
|
Dec 31, 2015 | $1.63 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
MacroGenics
MGNX
|
$0.20 B |
-0.000 M
|
USA
|
Mersana Therapeutics
MRSN
|
$64.24 M |
-0.000 M
|
USA
|
Zymeworks
ZYME
|
$1.01 B |
-0.000 M
|
Canada
|
Adicet Bio
ACET
|
$77.00 M |
0.008 M
|
USA
|
Nektar Therapeutics
NKTR
|
$0.17 B |
0.000 M
|
USA
|
Xencor
XNCR
|
$1.45 B |
0.000 M
|
USA
|
Iovance Biotherapeutics
IOVA
|
$1.83 B |
-0.000 M
|
USA
|
Adaptimmune Therapeutics
ADAP
|
$0.14 B |
0.000 M
|
UK
|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
BioAtla
BCAB
|
$28.91 M |
0.000 M
|
USA
|
Arcus Biosciences
RCUS
|
$1.23 B |
-0.000 M
|
USA
|
Blueprint Medicines
BPMC
|
$7.06 B |
-0.000 M
|
USA
|
Market Cap | = | CTMX Stock Price | * | CTMX Shares Outstanding |
= | $0.84 | * | 78.26 M | |
= | $65.55 M |